86 results about "Rabeprazole" patented technology

The invention relates to a high-purity sodium rabeprazole compound, belonging to the technical field of medicine. The method includes the following steps: dissolving crude sodium rabeprazole synthesized by the reaction of rabeprazole and sodium hydroxide in water, adjusting pH value to be faintly acid to neutral by using solid acid salt, and collecting precipitated solid; after dissolving the solid with organic solvent, conducting elution and purification by using eluting agent through macroporous adsorption resin, and collecting eluent; and adjusting the pH value of the eluent to be alkaline, and collecting the precipitated solid to obtain the pure sodium rabeprazole.

The present invention provides a process comprising admixing a thioether with about 1.05 to about 1.6 molar equivalents of an active chlorine-containing oxidant, preferably sodium hypochlorite, and about 2.5 to about 5.0 molar equivalents of an alkali metal base; and recovering a sulfoxide that is preferably pantoprazole, lansoprazole, omeprazole, or rabeprazole. The process may further comprise contacting the sulfoxide with a source of sodium ions, preferably sodium hydroxide, to produce the sodium salt of the sulfoxide. The invention also relates to novel chlorinated derivatives of pantoprazole including 5(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)-chloromethyl]sulfinyl]-1H- benzimidazole and 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)chlorohydroxymethyl] sulfinyl]-1H-benzimidazole and processes for making them. The invention also relates to processes of quantifying and identifying a compound other than pantoprazole in a mixture of pantoprazole and at least one other compound.

A stick of gum is provided containing therapeutic benefits of non-steroid anti-inflammatory drugs for inflammation in conditions such as arthritis, and also alleviates subsequent side effects of NSAID administration, as well as antacid effects from compounds such as an H2 antagonist (ranitidine, cimetidine, famotidine) and/or a proton pump inhibitor (such as lansoprazole, pantoprazole, omeprazole, esomeprazole or rabeprazole) and/or an acid pump antagonist selected from the group of soraprazan, AZD0865, YH1885 and CS-526.

The invention relates to a freeze-dry powder injection containing dextral rabeprazole and salt of the dextral rabeprazole and a preparation technique thereof. The dextral rabeprazole and the salt thereof are taken as medical active components and mixed with a plurality of pharmaceutically acceptable supplements to form a medical composition. The preparation method is that the dextral rabeprazole and the salt thereof are taken as raw materials, a plurality of supplements with special type and proportion are added, and the freeze-dry powder injection preparation for intravenous injection are prepared and developed according to the technical method described by the invention. The invention can be applied in urgent treatments of tachycardia type arrhythmia (including the atrial fibrillation, atrial flutter and sinus tachycardia) happened during operation.

The present invention provides a process comprising admixing a thioether with about 1.05 to about 1.6 molar equivalents of an active chlorine-containing oxidant, preferably sodium hypochlorite, and about 2.5 to about 5.0 molar equivalents of an alkali metal base; and recovering a sulfoxide that is preferably pantoprazole, lansoprazole, omeprazole, or rabeprazole. The process may further comprise contacting the sulfoxide with a source of sodium ions, preferably sodium hydroxide, to produce the sodium salt of the sulfoxide. The invention also relates to novel chlorinated derivatives of pantoprazole including 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)-chloromethyl]sulfinyl]-1H-benzimidazole and 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)-chlorohydroxymethyl]sulfinyl]-1H-benzimidazole and processes for making them. The invention also relates to processes of quantifying and identifying a compound other than pantoprazole in a mixture of pantoprazole and at least one other compound.

The invention provides a preparation method of a chiral sulfoxide medicament though catalysis of asymmetric oxidation of sulfides compounds. A chiral complex formed by quadridentate nitrogen organic ligand and metal manganese compound as a catalyst and hydrogen peroxide as an oxidant are used for asymmetric catalytic oxidation of prochiral thioether compound, so as to obtain the corresponding chiral sulfoxide medicament compounds including S-omeprazole, S-lansoprazole, S-pantoprazole, S-rabeprazole, R-Modafinil and R-sulindac. The reaction has the advantages of cleaness, mild reaction conditions, high conversion rate and antipodal selectivity, and shows industrial prospects.

The invention provides safe and effective methods for treating and preventing dysphagia, lower esophageal mucosal rings, esophageal strictures, achalasia, gastric mucosal injuries, and bacterial infections. The methods comprise administering at least one proton pump inhibitor, optionally in combination with antibacterial compounds. In one embodiment, the proton pump inhibitor is rabeprazole, a pharmaceutically acceptable salt thereof and/or a stereoisomer thereof.

A combination preparation for remedying the gastroesophageal reflux disease (GERD) and the functional dyspepsia is characterized in that the prescription of the combination preparation consists of a proton pump depressor and a gastrointestinal power drug of itopride; the proton pump depressor is selected from one of a Pantoprazole, a Omeprazole, a Esomeprazole, a Lansoprazole, a Rabeprazole, a Tenatoprazole and a Leminorazole, wherein the Pantoprazole is preferential, and at the same time the neutral form of the basic salt of the proton pump depressor is also included, such as Na^plus, Mg^2plus, Ca^2plus, K^plus or Li ^plus salt and a pure optical stereoisomer of the proton pump depressor or an active metabolite of the proton pump depressor; the gastrointestinal power drug is the itopride and a ramification of the itopride or one of the medicinal salts of the itopride; in the combination preparation, the weight ratio of the Pantoprazole and the itopride is 2 to 5 to 2 to 7. The invention has important affect for remedying the gastroesophageal reflux disease and the functional dyspepsia, and the preparation method of the invention is simple and convenient; the cost is low; the invention is fit for being orally taken by the patient; the invention has good conformance performance, high curative effect, low recrudescence rate and little adverse reaction.

The invention relates to a method for preparing sodium rabeprazole. The method is not subjected to concentration, extraction or lyophilization and comprises the steps of reacting rabeprazole with alkaline substances containing sodium ions at 50-55 DEG C and then adding an alkane solvent, thus dissolving out solid sodium rabeprazole.

The present invention relates to a process for the preparation of certain 2-pyridinyl)methyl]sulfinyl]-1H-benzimidazoles compounds. More specifically it relates to the preparation of an enantiomerically pure or optically enriched enantiomer of either omeprazole, pantoprazole, lansoprazole, or rabeprazole from a mixture containing the same using means for simulated moving bed chromatography.

The invention relates to a medical composition containing dextro-Rabeprazole and a preparation method thereof. The medical composition is prepared by taking dextro-Rabeprazole as the main active constituent and mixing dextro-Rabeprazole with pharmaceutically acceptable auxiliary materials. The composition can be prepared into various oral preparations according to the requirements, such as tablets, capsules, granules, dispersible tablets, chewable tablets, buccal tablets, effervescent tablets, effervescent granules and any other solid formulation, wherein, the unit preparation content of dextro-Rabeprazole is 2-50mg, preferably 10-40mg. The composition of the invention can be used for treating various digestive tract diseases, in particular to peptic ulcer.

The invention provides a composition of oryzanol and a proton pump inhibitor. The composition includes a clinical effective dose of proton pump inhibitor and an effective dose of oryzanol which are existent in different drug release units respectively; in a unit preparation, the clinical effective dose of proton pump inhibitor is 10-100 mg and the effective dose of oryzanol is 100-500 mg; the proton pump inhibitor in the composition is selected from omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole or pharmacologically suitable racemes, alkaline salt forms or single corresponding isomer forms thereof; and the drug release unit where the proton pump inhibitor is also includes an alkalizer. The composition can be used for treating peptic ulcer.

The present invention relates to calcium salts of rabeprazole and processes for preparing rabeprazole calcium. The invention also relates to pharmaceutical compositions that include the rabeprazole calcium and use of said compositions for the treatment or prevention of gastrointestinal ulcers

According to an existing method, acetic anhydride is adopted for a reaction when a formula III is synthesized from a formula IV, the reaction temperature is high, the reaction time is long, a large number of isomer byproducts can be generated in the reaction process, and the product purity is low. When the compound shown in the formula I is synthesized from free alkali of a compound shown in a formula II, halogenated alkane is used as a solvent and thionyl chloride is used as a chlorination reagent for reaction, alkali quenching, water washing extraction and salt formation after concentrationare needed for aftertreatment, the operation is complex, and the production period is long. According to the invention, p-toluenesulfonic acid is added for catalysis when the compound shown as the formula III is prepared, so that the reaction can be carried out at a relatively low temperature, the side reaction is greatly reduced, and the purity of the product is improved. When the compound shownin the formula I is prepared, ethyl acetate is used as a solvent, a product is gradually separated out along with the reaction, the product can be obtained through direct filtration after the reactionis completed, aftertreatment is simple, the product purity is high, and the method is suitable for industrial production.

The invention provides a eutectic crystal formed by orlistat and a proton pump inhibitor. The proton pump inhibitor is selected from one of omeprazole, esomeprazole, pantoprazole, rabeprazole and lansoprazole, or a pharmaceutically acceptable salt thereof. The eutectic crystal can simultaneously generate synergistic antibacterial and antitumor effects.

The invention relates to a simple synthesizing method of 2-pyridine methyl sulfide and related drugs. The method is characterized in that 2-methyl pyridine n-oxide is used as the raw material and pyridine n-oxide or dichloromethane is used as the solvent to have reaction with trifluoroacetic anhydride to obtain a trifluoroacetate intermediate, purification is not needed, the trifluoroacetate intermediate is allowed to have reaction with thiophenol under the catalysis of lithium bromide or tetrabutyl ammonium bromide and by using toluene or ethyl acetate as the solvent to generate the 2-pyridine methyl sulfide. The method is simple to operate, cheap in reagents, easy in reagent obtaining, mild in reaction conditions, wide in substrate applicability, good in position selectivity, high in yield and the like. In addition, the method is successfully applied to the synthesizing of omeprazole sulfide and rabeprazole sulfide, and the synthesizing method does not need catalysts.

The invention discloses a pharmaceutical composition for treating helicobacter pylori infection and application of the pharmaceutical composition. The pharmaceutical composition is prepared from, by weight, 7.5-40 parts of proton pump inhibitor, 150-1000 parts of antibiotic, 220-300 parts of bismuth agent and 60-140 parts of volatile extracts, wherein the proton pump inhibitor is selected from one of omeprazole, lansoprazole, esomeprazole, pantoprazole and rabeprazole; the antibiotic is selected from one of amoxicillin, clarithromycin, levofloxacin, metronidazole, furazolidone, tetracycline and minocycline; the bismuth agent is selected from one of bismuth potassium citrate, colloidal bismuth subcitrate and colloidal bismuth pectin; the volatile extracts are volatile components extracted from chenopodium ambrosioides and twigs and leaves of Pilular Adina. By means of the pharmaceutical composition, the eradication rate of helicobacter pylori can be improved, the effective rate is increased, and the drug resistance rate and the rate of adverse reactions are reduced.

They comprise insert granules of sugar/starch which are: initially coated with a non-alkaline active layer having the benzimidazole compound (omeprazole, lansoprazole, pantoprazole, rabeprazole, etc.), sodium and/potassium salts of acids of formula R—O—SO₃H wherein R is an alkyl radical of a (C₆-C₂₀)-fatty acid (preferably sodium lauryl sulfate), (C₆-C₂₀)-fatty acids (preferably oleic acid), sodium and/or potassium salts of (C₆-C₂₀)-fatty acids (preferably potassium oleate), sodium carboxymethyl starch and polyvinylpyrrolidone; secondly coated with a non-alkaline barrier layer having hydroxypropylmethylcellulose; and finally coated with an enteric layer. The preferred molar ratio (sodium lauryl sulfate):(oleic acid+potassium oleate) is between 4:1 and 6:1. All coatings are done with aqueous solutions, suspensions or dispersions at a relatively high temperature, and all dryings are done at a relatively low temperature and for a relatively short time. They are stable over time and useful for oral administration.

The invention discloses a method for preparing rabeprazole impurities through an HPLC method, and belongs to the fields of organic chemistry and medicine synthesis. The preparation method has the advantages of being simple, convenient to use, short in reaction time, high in target substance purity and helpful to the study of the rabeprazole impurities. The active pharmaceutical ingredient of rabeprazole is taken as the raw material, the HPLC method is adopted to prepare the target impurities, the chemical property of the impurities is analyzed, and bases are provided for the evaluation of thequality, safety and efficiency of the active pharmaceutical ingredient of the rabeprazole.